484 related articles for article (PubMed ID: 25200104)
1. Targeting FXR in cholestasis: hype or hope.
Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
[TBL] [Abstract][Full Text] [Related]
2. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
Fiorucci S; Mencarelli A; Palladino G; Cipriani S
Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
[TBL] [Abstract][Full Text] [Related]
3. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
4. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
Festa C; Renga B; D'Amore C; Sepe V; Finamore C; De Marino S; Carino A; Cipriani S; Monti MC; Zampella A; Fiorucci S
J Med Chem; 2014 Oct; 57(20):8477-95. PubMed ID: 25247751
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic functions of bile acids mediated by the farnesoid X receptor.
Stanimirov B; Stankov K; Mikov M
Acta Gastroenterol Belg; 2012 Dec; 75(4):389-98. PubMed ID: 23402081
[TBL] [Abstract][Full Text] [Related]
6. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
Ho PP; Steinman L
Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X receptor modulators (2011 - 2014): a patent review.
Sepe V; Distrutti E; Fiorucci S; Zampella A
Expert Opin Ther Pat; 2015; 25(8):885-96. PubMed ID: 26183029
[TBL] [Abstract][Full Text] [Related]
8. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
9. Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).
Sepe V; Renga B; Festa C; D'Amore C; Masullo D; Cipriani S; Di Leva FS; Monti MC; Novellino E; Limongelli V; Zampella A; Fiorucci S
J Med Chem; 2014 Sep; 57(18):7687-701. PubMed ID: 25162837
[TBL] [Abstract][Full Text] [Related]
10. Role of farnesoid X receptor in cholestasis.
Yuan ZQ; Li KW
J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832
[TBL] [Abstract][Full Text] [Related]
11. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.
Fiorucci S; Clerici C; Antonelli E; Orlandi S; Goodwin B; Sadeghpour BM; Sabatino G; Russo G; Castellani D; Willson TM; Pruzanski M; Pellicciari R; Morelli A
J Pharmacol Exp Ther; 2005 May; 313(2):604-12. PubMed ID: 15644430
[TBL] [Abstract][Full Text] [Related]
12. Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling.
Cipriani S; Renga B; D'Amore C; Simonetti M; De Tursi AA; Carino A; Monti MC; Sepe V; Zampella A; Fiorucci S
PLoS One; 2015; 10(7):e0129866. PubMed ID: 26177448
[TBL] [Abstract][Full Text] [Related]
13. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
14. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders.
Fiorucci S; Cipriani S; Baldelli F; Mencarelli A
Prog Lipid Res; 2010 Apr; 49(2):171-85. PubMed ID: 19932133
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor modulators 2014-present: a patent review.
Sepe V; Distrutti E; Fiorucci S; Zampella A
Expert Opin Ther Pat; 2018 May; 28(5):351-364. PubMed ID: 29649907
[TBL] [Abstract][Full Text] [Related]
16. Benefit of farnesoid X receptor inhibition in obstructive cholestasis.
Stedman C; Liddle C; Coulter S; Sonoda J; Alvarez JG; Evans RM; Downes M
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11323-8. PubMed ID: 16844773
[TBL] [Abstract][Full Text] [Related]
17. Agonist of farnesoid X receptor protects against bile acid induced damage and oxidative stress in mouse placenta--a study on maternal cholestasis model.
Wu WB; Xu YY; Cheng WW; Wang YX; Liu Y; Huang D; Zhang HJ
Placenta; 2015 May; 36(5):545-51. PubMed ID: 25747729
[TBL] [Abstract][Full Text] [Related]
18. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.
Zollner G; Marschall HU; Wagner M; Trauner M
Mol Pharm; 2006; 3(3):231-51. PubMed ID: 16749856
[TBL] [Abstract][Full Text] [Related]
19. Yangonin protects against estrogen-induced cholestasis in a farnesoid X receptor-dependent manner.
Dong R; Wang J; Gao X; Wang C; Liu K; Wu J; Liu Z; Sun H; Ma X; Meng Q
Eur J Pharmacol; 2019 Aug; 857():172461. PubMed ID: 31220436
[TBL] [Abstract][Full Text] [Related]
20. Oleanolic acid attenuates obstructive cholestasis in bile duct-ligated mice, possibly via activation of NRF2-MRPs and FXR antagonism.
Chen P; Li J; Fan X; Zeng H; Deng R; Li D; Huang M; Bi H
Eur J Pharmacol; 2015 Oct; 765():131-9. PubMed ID: 26297978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
